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Abstract
Background: Many authors advocate lipase as the preferred serological test for the diagnosis of
pancreatitis and a cut-off level of three or more times the upper limit of normal (ULN) is often quoted. The
literature contains no systematic review that explores alternative causes of a lipase level over three times
as high as the ULN. Such a review was therefore the objective of this study.
Methods: The EMBASE and MEDLINE databases (1985 to August 2013) were searched for all eligible
articles. Predetermined data were extracted and independently analysed by two reviewers.
Results: In total, data from 58 studies were included in the final analysis. The following causes other than
pancreatitis of lipase levels exceeding three times the ULN were found: reduced clearance of lipase
caused by renal impairment or macrolipase formation; other hepatobiliary, gastroduodenal, intestinal and
neoplastic causes; critical illness, including neurosurgical pathology; alternative pancreatic diagnoses,
such as non-pathological pancreatic hyperenzymaemia, and miscellaneous causes such as diabetes,
drugs and infections.
Conclusions: A series of differential diagnoses for significant serum lipase elevations (i.e. exceeding
three times the ULN) has been provided by this study. Clinicians should utilize this knowledge in the
interpretation and management of patients who have lipase levels over three times as high as the ULN,
remaining vigilant for an alternative diagnosis to pancreatitis. The medical officer should be aware of the
possibility of incorrect diagnosis in the asymptomatic patient.
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Introduction
Pancreatitis is an inflammatory disorder of the pancreas, the clini-
cal course of which ranges from mild disease to multiple organ
dysfunction and death.Guidelines for the diagnosis of pancreatitis
commonly stipulate the presence of two of the three following
criteria: typical abdominal pain; characteristic computed tomog-
raphy (CT) findings, and/or amylase and/or lipase levels of three
or more times the upper limit of normal (ULN).1
The sensitivity and specificity of serum lipase for pancreatitis at
a cut-off of three times the ULN range from 64% to 100% and
from 99% to 100%, respectively.2–5 In comparison, at the same
cut-off, the sensitivity and specificity of amylase range from 50%
to 78.6% and from 99% to 100%.2–5 Lipase provides increased
sensitivity in the diagnosis of acute pancreatitis caused by alcohol
consumption, and also in patients presenting later in their clinical
course.6
Lipase is an enzyme that catalyses the breakdown of
triglycerides.7 In addition to pancreatic acinar cells, lipase is found
in the gastrointestinal tract, including the oesophagus, duo-
denum, stomach and colon.7 Lipase has also been described in the
liver, heart, lungs and leukocytes.7,8 Pancreatic lipase content is
approximately 100 times that of the small intestine and liver, and
the pancreas to serum lipase concentration gradient is close to
20 000.7
In addition to pancreatitis, mild lipase elevations above the
ULN may be seen in a wide range of conditions, including peptic
ulcer disease and other hepatobiliary disorders.6 However, to the
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authors’ knowledge, no previous study has systematically
evaluated the aetiology of lipase levels of three or more times the
ULN.
Knowledge of the potential alternative causes of significantly
raised lipase is essential for clinicians because such levels may be
erroneously interpreted as indicative of pancreatitis in some cases.
This is especially important as lipase is advocated as the preferred
test for the diagnosis of pancreatitis in various guidelines and
much weight is given to levels that exceed the ULN by three or
more times.1,9
The literature was therefore reviewed for causes other than
pancreatitis of lipase levels of three or more times the ULN. The
objective of this review is not to suggest an alternative ‘cut-off’ for
raised lipase, but, rather, to alert the clinician to other potential
causes of significant lipase elevation (i.e. levels of three or more
times the ULN) in order to facilitate more accurate interpretation
and improve patient care.
Materials and methods
Eligibility criteria
The criteria for the inclusion of a study in this systematic review
required the reporting article to have been published after 1985.
Lipase levels of three or more times the ULN were defined as
representing significant elevation. At least one patient must have
clearly shown lipase levels of three or more times the ULN attrib-
utable to a cause other than pancreatitis, except in exceptional
circumstances as outlined below. Review articles, conference
abstracts and proceedings, and articles which made insufficient
explanation for the lipase result(s) were excluded from data
analysis.
Literature search
Using the keywords ‘pancreatitis’, ‘lipase’, ‘amylase’ and ‘diagnosis’,
the MEDLINE and EMBASE databases were searched for relevant
articles published from 1985 to August 2013. Methods of lipase
determination were initially labour-intensive and technically dif-
ficult, and more precise and faster assays were developed in the
late 1980s; therefore, this study targeted articles published from
1985 onwards.10–12 Additional searches were performed using
MEDLINE and EMBASE based on manual checking of the refer-
ence lists from all appropriate articles. Any further studies were
included if they met the inclusion criteria.
Study selection
Studies from the literature search were initially screened by
reviewing article titles and abstracts. Studies were excluded if the
review of the abstract identified any of the relevant exclusion
criteria. When study inclusion based on article title and abstract
was equivocal, the full text was reviewed and further screened for
inclusion and exclusion criteria. Articles deemed suitable for
inclusion were independently assessed by two reviewers before a
final decision on study eligibility was made.
Data collection
A standardized table was utilized in the process of extracting data
from each article. The information collected from each study
included: author(s); study year; city(s)/country(s) of study;
number of patients in the series (including numbers with elevated
lipase, and numbers with lipase levels of three or more times the
ULN); normal ranges of lipase and amylase; mean peak lipase
levels; mean peak amylase levels; evidence of pancreatitis in CT
and/or ultrasonography (US); presence of abdominal pain or ten-
derness; method(s) used to confirm diagnosis, and condition(s)
associatedwith lipase levels of three ormore times theULNas cited
in the article (Appendix). Obvious confounders, such as alcohol-
ism or renal failure, were noted. Individual patients in whom these
confounders coexisted with the cause under investigation were
generally excluded, except in studies outlining renal failure or
alcoholism as potential causes of significant lipase elevation.
Causes of lipase of three or more times the ULN in each study
were categorized as either (i) ‘probable’ or (ii) ‘possible’. These two
groups were defined according to: (i) the number of study(s)
supporting the cause of raised lipase; (ii) the strength of confirma-
tory evidence, such as cross-sectional imaging, laparotomy/
surgical findings and/or specific serological or other tests; (iii) the
possibility of underlying subclinical pancreatitis based on the
mechanism in question, and/or (iv) the presence or absence of
other potential causes of raised lipase.
Formulation of results
Qualitative items from each study, primarily representing differ-
ent causes of lipase levels of three or more times the ULN, were
synthesized and divided into four final groups: (i) reduced clear-
ance or physiological causes; (ii) intra-abdominal pancreatic and
non-pancreatic causes; (iii) critical illness, and (iv) other. Neither
a quantitative analysis nor a formal meta-analysis could be con-
ducted as a result of the significant heterogeneity among the arti-
cles and because of the inclusion of case reports in the final
analysis. This systematic review was completed in line with
PRISMA (preferred reporting items for systematic reviews and
meta-analyses) guidelines.13
Results
The process of study selection and exclusion is outlined in Fig. 1.
Data from 58 studies were included in the final qualitative analysis
from which probable causes other than pancreatitis for lipase
levels of three or more times the ULN were drawn.
Three of the 58 articles indicated potential associations with
lipase levels of three or more times or close to three times the ULN
without conclusive evidence (Table 1). Table 2 summarizes all
potential causes of lipase levels of three or more times the ULN
without associated pancreatitis, categorized into the four groups
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outlined above. The strength of evidence for each alternative cause
is also outlined in Table 2.
Alternative causes of lipase levels of three or more
times the ULN
Reduced lipase clearance/physiological causes
There is no correlation between the cause of acute kidney injury
(AKI) and raised lipase.14–16
Intra-abdominal non-pancreatic and pancreatic
causes (non-traumatic)
Hepatocellular carcinoma, bowel cancer with liver metastases and
unspecified metastatic bowel and gastric cancer can all be consid-
ered as possible causes of lipase levels of three or more times the
ULN.11,14,17 Patients with these diagnoses in the respective series
often had a normal pancreas on US and/or CT scanning, and a
negative laparotomy when performed (Appendix).
Non-pathological pancreatic hyperenzymaemia is a more
recently described phenomenon with good evidence as a cause of
significant lipase elevation.18–22 It is characterized by the absence of
identifiable pancreatic disease in the presence of elevated pancre-
atic enzyme levels.23
Elevated lipase levels may also be seen post-endoscopic retro-
grade cholangiopancreatography (ERCP), without any associated
evidence of pancreatitis.24 Gottlieb et al. showed that lipase levels
of 1000 units/l (normal range: 40–240 units/l) after ERCP had
Figure 1 Study selection process. ULN, upper limit of normal
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specificity of only 55% for pancreatitis.24 The existence of foci of
pancreatitis cannot be disproved, however, and the clinical signifi-
cance of this lipase rise is uncertain.
Lipase in critical illness
Multi-trauma patients without head injury have been reported
to have significant lipase elevations without strong radiological or
operative evidence for pancreatitis.8,11,25–27 Broadly, these patients
have sustained blunt abdominal or pelvic trauma, in some cases
with associated liver injury.8,11,25,27 However, it is very difficult
to disprove underlying subclinical pancreatitis in such patients,
and therefore multi-trauma cannot be thought of as a probable
cause of lipase levels of three or more times the ULN without
pancreatitis.
Some authors have also pointed to lipase elevations of three or
more times the ULN in non-surgical intensive care unit (ICU)
patients with such diagnostic categories as septic shock and res-
piratory failure; underlying pancreatitis remains a significant pos-
sibility here (Table 3).25,26
Other causes of lipase levels of three or more
times the ULN
Diabetes Malloy et al. showed that a very small proportion of
patients with asymptomatic type 2 diabetes had lipase levels of
three or more times the ULN; this may thus be a possible cause
of significant lipase elevation.28
Abdominal pain is a common finding in diabetic ketoacidosis
(DKA); however, in the studies outlined in Table 2,29–33 DKA
patients with elevated lipase and abdominal pain rarely showed
clinical and/or radiological pancreatitis (see also Appendix).
Drugs Despite the association of chronic alcoholism with chronic
pancreatitis, some authors have shown lipase levels of three or
more times the ULN in otherwise asymptomatic alcoholics.34
Some patients also experienced significant abnormalities in serum
lipase after the administration of the dipeptidyl peptidase-4
(DPP-4) inhibitors, sitagliptin and saxagliptin, for the treatment
of type 2 diabetes.35 None of these patients had clinical features of
pancreatitis and lipase levels normalized in most after drug with-
drawal.35 Lobo et al. used intramuscular morphine (10 mg) and
prostigmine (1 mg) for the investigation of sphincter of Oddi
dysfunction (SOD).36 Surprisingly, both patients with proven
SOD and healthy controls showed a lipase rise that sometimes
exceeded three times the ULN.36 Provocation did not induce pain
in any of the healthy controls.36
Infection Yoffe et al. found that some asymptomatic patients with
chronic hepatitis C virus (HCV) infection demonstrated lipase
levels of three or more times the ULN; lipase levels often normal-
ized in patients who responded to HCV therapy.37 Patients with
human immunodeficiency virus (HIV) may also sometimes
develop high lipase levels, although the contribution of the virus
alone to this abnormality is debatable and at best possible.38 Gas-
troenteritis is also a possible consideration in patients with
elevated lipase without pancreatitis, but more evidence is
required.11,15
Miscellaneous causesSarcoidosis has been reported in a single case
as a possible cause of lipase levels of three or more times the
ULN.39 This patient had no clinical or imaging features of pan-
creatitis.39 Coeliac disease and inflammatory bowel disease (IBD)
were associated with lipase elevations that came close to but did
not reach three or more times the ULN40–42 (Table 1).
Discussion
Summary of evidence
This systematic, qualitative review has outlined a wide variety of
causes of lipase levels of three or more times the ULN with the
purpose of significantly aiding the clinician in his or her interpre-
tation of this result. Although the specificity of lipase testing for
pancreatitis at a cut-off of three or more times the ULN is >99%,
it is essential for health care providers to understand other poten-
tial causes of this abnormality.2–5
As Table 2 shows, there are many potential causes other than
pancreatitis for the significant elevation of lipase levels. Reduced
clearance of lipase from the circulation can occur with renal
impairment or macrolipase formation. Lipase may also be
elevated as a result of other intra-abdominal pathologies arising
from the stomach, bowel and hepatobiliary tract, and from neo-
plastic disease. Diabetes, drugs and infection can also be respon-
sible for lipase levels of three or more times the ULN.
Table 3 explains the possible pathogeneses of some of these
causes of elevated serum lipase.
Data bias and study limitations
As a result of the heterogeneous nature of the studies included,
and often insufficient and poorly comparable quantitative data,
Table 1 Possible other causes of lipase levels of three or more times
the upper limit of normal (ULN)
Authors,
year
Possible association(s) with lipase of three or
more times the ULN
Bokemeyer,
200240
IBD: three of 70 and three of 66 patients with UC
and CD, respectively, had lipase levels over twice
the ULN; however, the potential number of
patients with lipase levels of three or more times
the ULN is not explicitly recorded in the article
Carroccio
et al.,
200641
Coeliac disease: adults and children with coeliac
disease had lipase elevations of, respectively, up
to 2.5 and 2.1 times the ULN at disease diagnosis
Heikius et al.,
199942
IBD: serum lipase was elevated by up to 2.9 times
the ULN
CD, Crohn's disease; IBD, inflammatory bowel disease; UC, ulcerative
colitis.
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Table 2 Summary of causes of significantly raised lipase without pancreatitis
Categories of causes Strength of evidence: study type(s) and method(s) of diagnosis confirmation
Reduced clearance/physiological
Renal impairment
AKI8,14-16
CRF with or without haemodialysis or continuous ambulatory peritoneal dialysis11,49,50
AKI: case series (×2), case–control study (×2); blood tests ± US, CT, laparotomy
CRF: case series (×1), case–control study (×1), cohort study (×1); blood tests ± US +
?others (NR)
Macrolipase51-56
Potential complexes: IgG, IgA, IgM, α-2-microglobulin
Potential associated conditions: coeliac disease, Crohn's disease,
hypergammaglobulinaemia, liver cirrhosis, multiple myeloma, systemic lupus
erythematosus
Macrolipase: case report (×6); blood tests ± US, CT, laparotomy, ERCP, urine amylase,
urine lipase, chromatography, immunoprecipitation assays
Intra-abdominal pancreatic and non-pancreatic (non-traumatic)
Hepatobiliary
Biliary atresia57
Cholecystitis11,14,15,43
Cholangitis15
Liver necrosis8
?Post-ERCPa24
Biliary atresia: case series; blood tests + US ± MRI
Cholecystitis: case series (×2), case–control study (×2); blood tests ± US, CT,
laparotomy
Cholangitis: case–control study; blood tests ± US, CT, ?others (NR)
Liver necrosis: case–control study; blood tests ± US, CT, laparotomy
Post-ERCP: case series; blood tests
Gastroduodenal
Gastric perforation58
Peptic ulcer disease with or without perforation2,4,5,14,43
Gastric perforation: case report; blood tests + CT, laparotomy
Peptic ulcer disease: case series (×2), case–control study (×1), cohort study (×2); blood
tests ± US, CT, MRCP, ERCP, endoscopy, laparotomy
Bowel
Bowel necrosis and/or perforation8,15
Bowel obstruction2,15,59
Bowel necrosis/perforation: case–control study (×2); blood tests ± US, CT, laparotomy
Bowel obstruction: case report (×1), case–control study (×1), cohort study (×1); blood
tests ± US, CT, MRCP, ERCP, laparotomy
Neoplasms
Acinar cell carcinoma of pancreas60-62
Others: ?hepatocellular carcinoma, ?metastatic bowel cancer, ?metastatic gastric
cancer, ?othersa11,14,17
Acinar cell carcinoma: case report (×1), case series (×2); blood tests ± US, CT, biopsy,
laparotomy
Other neoplasms: case series with <10 patients (×1), case series (×1), case–control
study (×1); blood tests ± US, CT, laparotomy
Non-neoplastic, pancreatic
Non-pathological pancreatic hyperenzymaemia18-22
Pancreas transplant rejection63
Non-pathological pancreatic hyperenzymaemia:– observational study/case series (×4),
cohort study (×1); blood tests ± US, CT, MRI (including MRCP and MRCP-S), ERCP,
secretin-cerulein test, urine amylase
Pancreas transplant rejection: case series; blood tests + pancreatic biopsy
Other
Ruptured AAA2
Intra-abdominal haemorrhage from other sources – ruptured ectopic pregnancy,
ruptured ovarian cyst, ?others64,65
Peritonitis11
Ruptured AAA: cohort study; blood tests ± US, CT, MRCP, ERCP
Haemorrhage from other sources: case report (×2); blood tests ± US, CT, laparotomy
Peritonitis: case–control study; blood tests + ?others (NR)
Critical illness
Neurosurgical
ICH with or without craniotomy8,25,66-68
TBI/head injury without intracranial haemorrhage25,67,69
ICH: observational study/case series (×2), case–control study (×3); blood tests ± US, CT,
craniotomy
TBI:– observational study/case series (×1), case–control study (×1), cohort study (×1);
blood tests ± US, CT, craniotomy
?Other critically ill/intensive care unit patients, including those with multi-system
traumaa25-27,67,68
See text and Appendix
Other
Diabetes
Type 1 DM (insulin-dependent diabetes mellitus)14,70
DKA (adults and children)29-33
?Type 2 DM28
Type 1 DM: case series (×1), cohort study (×1); blood tests ± ?others (NR)
DKA: case series with <10 patients (×1), case series (×1), cohort study (×3); blood tests
± CT, other imaging (not specified)
Type 2 DM: case–control study; blood tests + ?others (NR)
Drugs
Alcohol (chronic alcoholism)34
Morphine + prostigmine provocation (in healthy controls and sphincter of Oddi
dysfunction)36
?Sorafenib71
?Nilotinib72
?DPP-4 inhibitors (sitagliptin and saxagliptin)35
?Others
Chronic alcoholism: case–control study; blood tests + ?others (NR)
Morphine + prostigmine provocation: cohort study; blood tests + CT, ERCP, HIDA scan
Sorafenib: case series; method of diagnosis confirmation NR
Nilotinib: case series; blood tests + ?others (NR)
DPP-4 inhibitors: cohort study; blood tests only
Infection
HCV37
? HIV38
?Gastroenteritis11,15
?Others (e.g. ? CMV)11
HCV: case–control study; blood tests ± US
HIV: observational study; blood tests ± US, CT
Gastroenteritis: case–control study (×2); blood tests ± US, CT, ?others (NR)
CMV: case–control study; blood tests + ?others (NR)
Miscellaneous
?Sarcoidosis39
?Renal transplant rejection11
Sarcoidosis: case report; blood tests + US, CT, ERCP, gel filtration chromatography, liver
biopsy
Renal transplant rejection: case–control study; blood tests + ?others (NR)
aSee text.
Possible causes of significantly raised lipase, as defined in the Methods section, are denoted by a preceding ‘?’.
‘Blood tests’ as one method of confirming a diagnosis implies the use of standard accepted serological tests for each respective condition (if applicable). Clinical assessment is by
implication a part of diagnosis confirmation, and is thus not explicitly mentioned.
AAA, abdominal aortic aneurysm; AKI, acute kidney injury; CMV, cytomegalovirus; CRF, chronic renal failure; CT, computed tomography; DKA, diabetic ketoacidosis; DM, diabetes mellitus;
DPP-4, dipeptidyl peptidase-4; ERCP, endoscopic retrograde cholangiopancreatography; HCV, hepatitis C virus; HIDA, hepatobiliary iminodiacetic acid; HIV, human immunodeficiency
virus; ICH, intracranial haemorrhage; Ig, immunoglobulin; MRCP, magnetic resonance cholangiopancreatography; MRCP-S, secretin-enhanced MRCP; MRI, magnetic resonance imaging;
NR, not recorded; TBI, traumatic brain injury; US, ultrasonography.
HPB 103
HPB 2015, 17, 99–112 © 2014 International Hepato-Pancreato-Biliary Association
quantitative analyses were not performed here. Some of the
proposed causes of lipase levels of three or more times the
ULN are at best speculative, but every effort has been made to
include only those causes for which there are plausible mecha-
nism(s) and for which there exists evidence from multiple
sources. An attempt was made in the data collection process to
account for underlying conditions that may confound lipase
values, such as alcoholism and the presence of renal impairment.
Although the methods by which diagnoses were confirmed were
recorded, there will inevitably be cases in which underlying
mild pancreatic inflammation may have been missed in the
respective studies; this is especially likely in retrospective series.15
Normal findings in CT, ERCP, US and even laparotomy may
not always preclude histological pancreatitis.43–45 Indeed, the CT
scan may be normal in up to 25% of patients with clinical
pancreatitis.30,46
Lipase assays
It is important for clinicians to understand that assay interference
and the detection of non-pancreatic lipases is possible; this in
itself will not usually produce levels of three or more times the
ULN, but can definitely alter lipase results.7,47 Demanet et al., for
example, showed large increases in serum lipase after the admin-
istration of i.v. heparin to patients; the Ektachem andWako assays
were used in this study.48 When assay interference is suspected,
clinicians should contact their clinical chemistry laboratory for
clarification.
Implications and future perspectives
Lipase remains a good serological test for the diagnosis of pan-
creatitis. However, as shown by this study, levels of three or more
times the ULN do not automatically confirm the diagnosis and
many possible differential diagnoses exist. The diagnosis of
Table 3 Possible pathogeneses of alternative causes of significantly raised lipase
Reduced clearance/physiological
Renal impairment
• Lipase handling and metabolism: glomerular filtration is primarily responsible for the removal of lipase from the serum; the majority of lipase
is then reabsorbed by renal tubules with subsequent intra-renal degradation.7,43,73 Liver, lungs and spleen also likely involved in lipase
metabolism7,74
• Raised lipase in renal impairment: reduced glomerular filtration at least partially explains this.50 Other mechanisms also seem to exist as
lipase levels in individuals do not correlate well with changing renal function75
• Haemodialysis and CRF patients: additional possibilities include subclinical foci of pancreatitis and increased lipase reabsorption in the
intestine49,50
Macrolipase
• Enlarged lipase molecule: may artificially elevate serum lipase measurements caused by reduced renal filtration53,54
• Presence of macrolipase may sometimes indicate an increased risk for associated disorders, such as autoimmune or lymphoproliferative
disease51,52
Intra-abdominal pancreatic and non-pancreatic causes (other than pancreatitis)
• Inflammation: pancreas probably highly sensitive to inflammation in adjacent organs/structures, such as the biliary tract and gastrointestinal
tract, with subsequent increases in serum lipase caused by inflammation of these organs11,43
• Obstruction: biliary regurgitation into the pancreas from distal obstruction may induce pancreatic inflammation; biliary, pancreatic duct or
bowel obstruction may also cause increased bloodstream diffusion of pancreatic enzymes4,11,14
• Alternative sources of lipase: stomach, small bowel, liver, gallbladder and other surrounding organs may potentially act as non-pancreatic
sources of lipolytic enzymes14
• Peritonitis: mechanisms not clear with regards to peritoneal irritation (e.g. intra-abdominal haemorrhage) and elevated serum lipase65
• Impaired hepatic function: reduced hepatic metabolism of lipase may occur with impaired hepatic function (e.g. chronic liver diseases like
biliary atresia)57,74
• Neoplasia: lipase elevation may be related to biliary or pancreatic ductal obstruction, formation of macrolipases, or (functional) tumour mass
lipase production/hypersecretion17,60,62
• Non-pathological pancreatic hyperenzymaemia: mechanisms not yet characterized, although a genetic basis should be entertained23
Critical illness
• ICU patients with critical illness/multi-organ failure: pancreatic hypoperfusion with cellular stress may be responsible for lipase elevations;25
alternatively, pancreatic enzymes in the gut may enter the submucosa and subsequently the systemic circulation during times of gut
ischaemia from reduced splanchnic flow25,26
• Neurosurgical patients with severe head injuries: exocrine pancreatic enzyme production may be activated through central pathways, such as
increased vagal tone, altered adrenergic stimulation, and/or release of activating hormones such as cholecystokinin66,68
Some alternative causes
Diabetic ketoacidosis and type I DM
• Possible causes of raised lipase in DKA: may include relative renal hypoperfusion and thus reduced serum clearance of the enzyme;30
alternatively, impaired pancreatic and/or splanchnic flow, in addition to non-pancreatic release of lipolytic enzymes, may be contributing
factors.17,54,56
• In DKA and recent-onset type 1 DM in general: inflammation from immune-mediated β-cell destruction could potentially ‘spill over’ into the
exocrine pancreas, with subsequent acinar cell damage14,30,70
CRF, chronic renal failure; DKA, diabetic ketoacidosis; DM, diabetes mellitus; ICU, intensive care unit.
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pancreatitis based on clinical and serological features will some-
times generate false positives as many of the alternative diagnoses
described in the current review also present with abdominal pain.
In less clear circumstances, the simultaneous measurement of
both amylase and lipase should also be considered, althoughmany
authors doubt that this practice enhances diagnostic accu-
racy.1,2,6,15 Furthermore, the conditions presented here as causing
lipase levels of three or more times the ULN often also induce
elevations of serum amylase, which may negate any added diag-
nostic utility afforded by amylase measurement.6 Alternative sero-
logical tests may refer to amylase isoenzymes, immunoreactive
trpysinogen (IRT) and elastase-1.6 The latter two tests offer little
help over lipase or amylase as routine diagnostic tests for pancrea-
titis, although they may be helpful in the event that a diagnosis of
pancreatitis is doubtful.6 Another potential course of action in
cases of diagnostic difficulty is to lower the threshold for abdomi-
nal CT, which may pick up alternative causes for the patient’s
presentation.
Overall, elevated lipase levels, like raised amylase levels, can
occur in both asymptomatic patients and patients with a myriad
of differing medical and surgical conditions. Knowledge of these
different aetiologies will aid clinicians in the decision making and
treatment of patients with significantly raised lipase, especially in
patients with equivocal lipase levels.
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Study data
Author(s),
year
Hospital, country
Type of study
Patients in series and
patients with raised
lipase levels, n
Normal
range
of lipase
Normal
range of
amylase
Peak amylase level
(non-pancreatitis),
mean (range)
Peak lipase level
(non-pancreatitis),
mean (range)
Imaging
(CT ± others)
Presence of
abdominal pain/
tenderness
Akaza et al.,
200771
Fukuoka, Osaka,
Sapporo, Tsukuba
and Tokyo, Japan
Prospective
non-randomized
open label study
129
73 had ↑ lipase w/o
pancreatitis
8 had levels >5 × ULN,
and 32 had levels
>2–5 × ULN
NR NR NR NR NR 0/73 patients
with ↑ lipase
Argiris et al.,
199938
New York, USA
Prospective
observational study
86
26 had ↑ lipase w/o
pancreatitis
Number with lipase
levels ≥ 3 × ULN NR
10–70 U/l 25–125 U/l 117 (range
17–806)
56 (range 9–482) No US or CT features
of pancreatitis in
6 patients with ↑
lipase; 1 patient
had mild pancreatic
duct dilatation and
‘minimal pancreatic
enlargement;’
imaging not
performed in others
due to no clinical
suspicion
5/86 patients
with ↑ lipase
(epigastric
discomfort or
dyspepsia)
(pancreatitis
was not
suspected)
Ashley &
Lauwers,
200260
Boston, USA
Case report
1
Had lipase level ≥ 3 ×
ULN
NR NR 42 1614 No CT, US or MRI
features of
pancreatitis
Nil
Asvesta
et al.,
198834
Thessaloniki, Greece
Case–control study
168
72 had ↑ lipase
At least 10 had lipase
levels ≥ 3 × ULN
0–160 U/l NR NR 366 (79 in
controls)
NR 0/168 patients
with ↑ lipase
Bokemeyer,
200240
Minden, Germany
Prospective
observational study
136
19 had ↑ lipase w/o
pancreatitis (11 had
CD, 8 had UC)
6 had lipase levels >2 ×
ULN w/o pancreatitis
0–60 U/l 28–100 U/l NR (1 patient had
levels > 2 ×
ULN)
NR No US features of
pancreatitis in all
19 patients with ↑
lipase
0/19 patients
with ↑ lipase
Brooks et al.,
200959
Cleveland, USA
Case report
1
Had lipase level ≥ 3 ×
ULN
12–70 U/l 0–137 U/l 1241 2664 No CT features of
pancreatitis
Yes (epigastric
pain)
Carroccio
et al.,
200641
Palermo, Italy
Prospective
observational study
202 (90 adults, 112
children)
19 adults and 21
children had ↑ lipase
w/o pancreatitis
No patient had lipase
levels ≥ 3 × ULN
(peak was 2.5 × ULN)
20–270 IU/l
(adults);
variable for
children
10–160 IU/l
(adults);
variable for
children
240 (median)
(adults); 1.4 ×
ULN (median)
(children)
432 (median)
(adults); 1.3 ×
ULN (median)
(children)
No US features of
pancreatitis in all
202 patients
10/90 adults and
9/112 children
(‘recurrent
abdominal
pain’)
Catton &
Lobo,
201058
Nottingham, UK
Case report
1
Had lipase level ≥ 3 ×
ULN
23–300 IU/l 30–110 IU/l 380 4398 No CT features of
pancreatitis
Yes (epigastric
pain)
Chase et al.,
199643
Chattanooga, USA
Retrospective case
series
306
208 had non-pancreatic
abdominal pain
26/208 had ↑ lipase
4 had lipase levels ≥ 3
× ULN
5–208 U/l 30–110 U/l N/Ad (maximum
385)
N/Ad (maximum
3685)
NR 26/26 patients
with ↑ lipase
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Author(s),
year
Hospital, country
Type of study
Patients in series and
patients with raised
lipase levels, n
Normal
range
of lipase
Normal
range of
amylase
Peak amylase level
(non-pancreatitis),
mean (range)
Peak lipase level
(non-pancreatitis),
mean (range)
Imaging
(CT ± others)
Presence of
abdominal pain/
tenderness
Chen et al.,
199649
Taipei, Taiwan
Retrospective case
series
84
22 had ↑ lipase w/o
pancreatitis
4 had levels ≥ 3 × ULN
w/o pancreatitis
<190 U/l <180 IU/l 127 ± 17
(haemodialysis
patients); 192.1
± 24.5 (no
dialysis)
206 ± 35
(haemodialysis
patients); 146.1
± 18.4 (no
dialysis)
No US features of
pancreatitis in all
22 patients with ↑
lipase
0/22 patients
with ↑ lipase
Denz et al.,
200725
Berlin, Mannheim and
Karlsruhe, Germany
Prospective
observational study
66
52 had ↑ lipase
38 had lipase levels ≥ 3
× ULN
<150 U/l NR NR NR CT showed features
of pancreatitis in
7/20 patients in
which it was done;
No CT features of
pancreatitis in 13
patients with lipase
≥ 3 × ULNbb
NR
Diani et al.,
199817
Pavia and Varese,
Italy
Retrospective case
series
4
All 4 had ↑ lipase w/o
pancreatitis
3 had lipase levels ≥ 3
× ULN w/o
pancreatitis
8–57 U/l NR Within normal
limits (all
patients)
197 (patient 1);
120 (patient 2);
351 (patient 3);
412 (patient 4)
No US features
negative of
pancreatitis in all
patients; no CT
features of
pancreatitis in at
least 2 patients
NR
Duerksen
et al.,
200039
Winnipeg, Canada
Case report
1
Had lipase level ≥ 3 ×
ULN
<190 IU/l <120 IU/l 350 2000 No CT or US features
of pancreatitis
Nil
Frank &
Gottlieb,
199914
Landshut, Germany;
Indianapolis, USA
Retrospective case
series
25
All 25 had ↑ lipase
All 25 had lipase levels
≥ 3 × ULN
40–240 U/l 25–115 U/l N/Ad N/Ad NR 19/25 patients
with ↑ lipase
Gomez et al.,
20122
Nottingham, UK
Retrospective cohort
study
2979
18 had lipase levels ≥ 3
× ULN w/o
pancreatitisi
0–300 U/l 0–100 U/l NR NR No CT features of
pancreatitis in all
18 patients
18/18 patients
(acute
abdominal
pain)
Goto et al.,
200051
Akita and Matsumoto,
Japan
Case report
1
Had lipase level ≥ 3 ×
ULN
29–220 IU/l 115–360 IU/l 625 3338 No US features of
pancreatitis
Nil
Gottlieb
et al.,
199624
Indianapolis, USA
Prospective case
series
231
Number with ↑ lipase
NR
193 patients did not
have pancreatitis
40–240 U/l 25–115 U/l 200 ± 13 (cf. 657
± 104 for
pancreatitis
patients)
2444 ± 288 (cf.
9879 ± 1480
for pancreatitis
patients)
NR 70/193 patients
w/o
pancreatitis
had abdominal
pain
Gullo, 199618 Bologna, Italy
Prospective case
series
18
All 18 had ↑ lipase
At least 6 had lipase
levels ≥ 3 × ULN
24–270 IU/l 0–220 IU/l NR (range
1.4–4.1 × ULN)
NR (range
1.5–7.7 × ULN)
No CT or US (×2)
features of
pancreatitis in all
patients
0/18 patients
Gullo, 200019 Bologna, Italy
Prospective
observational study
102j
19 had ↑ lipase w/o
pancreatitis
7 had lipase levels ≥ 3
× ULN w/o
pancreatitis
24–270 IU/l 0–220 IU/l NR (range
1.3–5.2 × ULN)
NR (range 1.6–18
× ULN)
No US features of
pancreatitis in all
19 patients with ↑
lipase
0/19 patients
with ↑ lipase
Gullo et al.,
200620
Bologna, Italy
Prospective
observational study
18w
16 had ↑ lipase w/o
pancreatitis
7 had lipase levels ≥ 3
× ULN w/o
pancreatitis
13–60 IU/l 13–53 IU/l
(pancreatic
isoamylase)
NR (range
∼0.8–3.9 ×
ULN)
(pancreatic
isoamylase)
NR (range
∼0.8–6.4 ×
ULN)
No US, CT or MRI
features of
pancreatitis in all
patients
0/18 patients
Gullo, 200721 Bologna, Italy
Prospective
observational study
42w
38 had ↑ lipase w/o
pancreatitis
30 had lipase levels ≥ 3
× ULN w/o
pancreatitis at some
point during study
13–60 IU/l 28–110 IU/l NR 255 (mean of
peak levels in
each patient
over 5 days)
No US or CT features
of pancreatitis in all
patients; No MRI
features of
pancreatitis in
36 patients
0/42 patients
Gumaste
et al.,
19934
New York, USA
Prospective cohort
study
170 (95 w/o
pancreatitis + 75 with
pancreatitis)
10 had ↑ lipase w/o
pancreatitis
1 had lipase levels ≥ 3
× ULN w/o
pancreatitis
31–213 U/l ?40–100 U/l N/Ad N/Ad NRf 95/95 patients
w/o
pancreatitis
(acute
abdominal
pain)
Haddad
et al.,
200429
Indianapolis, USA
Prospective cohort
study
50
20 had ↑ lipase w/o
pancreatitis
7 had lipase levels ≥ 3
× ULN w/o
pancreatitis
15–120 U/l
(vitros);
5–51 U/l
(colorimetric)
25–115 U/l
(vitros);
25–115 U/l
(Catachem)
162 ± 152 in
DKA patients
with ↑ lipase or
amylase (cf. 38
± 10 for DKA
patients with
normal
enzymes)
404 ± 385 in
DKA patients
with ↑ lipase or
amylase (cf. 46
± 27 for DKA
patients with
normal
enzymes)
CT features of
pancreatitis in 1
patient (performed
in 3 patients with
lipase ≥ 3 × ULN)
36/50x patients
(abdominal
pain and/or
vomiting)
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Author(s),
year
Hospital, country
Type of study
Patients in series and
patients with raised
lipase levels, n
Normal
range
of lipase
Normal
range of
amylase
Peak amylase level
(non-pancreatitis),
mean (range)
Peak lipase level
(non-pancreatitis),
mean (range)
Imaging
(CT ± others)
Presence of
abdominal pain/
tenderness
Heikius
et al.,
199942
Oulu, Finland
Prospective
observational study
237aa
16 had ↑ lipase w/o
pancreatitis
No patient had lipase
levels ≥ 3 × ULN
(peak was 2.9 × ULN)
<160 U/l 70–300 U/l 176 (range
1.1–1.9 × ULN)
66 (range 1.1–2.9
× ULN)
US showed
increased/patchy
echogenicity of the
pancreas in 6/38
patients with ↑
lipase or amylase
NR
Justice et al.,
199466
Savannah, USA
Prospective case
series
38 (37 w/o pancreatitis
+ 1 with pancreatitis)
24 had ↑ lipase w/o
pancreatitis
Number with lipase
levels ≥ 3 × ULN NR
23–208 U/l 30–110 U/l 140 ± 109 712 ± 614 No CT features of
pancreatitis in the
3 patients it was
performed in
NR
Keating &
Lowe,
200252
St Louis, USA
Case report
1
Had lipase level ≥ 3 ×
ULN
20–200 U/l 15–130 U/l 1143 (range
119–1143 over
2 months)
1139 (range
694–3095 over
2 months)
No CT or US (×2)
features of
pancreatitisg
Yes (lower
abdominal
cramps)
Klassen
et al.,
199663
Baltimore, USA
Prospective case
series
69 (68 w/o pancreatitis
+ 1 with pancreatitis)
Number with ↑ lipase
NR
23–208 IU/l 30–110 U/l 341 ± 40 1548 ± 222 NR NR
Klimstra
et al.,
199261
New Haven and
Washington, USA
Retrospective case
series
28
4 had ↑ lipase
At least 1 had lipase
levels ≥ 3 × ULN
0–1 Teitz units NR NR NR (maximum 20
Teitz units)
NR NR
Lando et al.,
201235
Alexandria and
Washington, USA
Retrospective cohort
study
90
31 had ↑ lipase w/o
pancreatitis
Number with lipase
levels ≥ 3 × ULN NRh
∼60–65 U/l
(ULN)h
NR NR (maximum
was 100 U/l
above normal)
NR (maximum
453)
No imaging done
(patients
asymptomatic)
0/90 patients
Lee et al.,
201067
Taipei, Taiwan
Case–control study
89
43 had ↑ lipase or
amylase (exact
number with ↑ lipase
NR)
≤200 U/l ≤190 U/l NRt NRt See footnoteu Difficult to
assess/NRv
Liu et al.,
200168
Chicago, USA
Case–control study
75
11 had ↑ lipase and
amylase levels
Number with lipase
levels ≥ 3 × ULN NR
0–55 U/l 0–125 U/l 402 474 US done in 3/11
patients with ↑
lipase, US + CT
done in 3/11
patients; nil
imaging in 5
patients – no US or
CT features of
pancreatitis in
these patients
0/11 patients
with ↑ lipasek
Lobo et al.,
200736
Nottingham, UK
Prospective cohort
study
44 (20 controls + 24
patients with SOD)
At least 17 controls and
23 SOD patients had
↑ lipase levels
Exact number with
lipase levels ≥ 3 ×
ULN NR
23–300 U/l 30–110 U/l ∼7 × ULN (in
controls,
post-provocation
with morphine
and
prostigmine)
∼10 × ULN
(median – in
controls,
post-provocation
with morphine
and
prostigmine);
levels
increased up
to 50 × ULN in
SOD patients
(exact values
NR)
NR 0/20 controls
(post-provocation);
20/24 SOD
patients
(post-provocation)
Lott et al.,
198611
Columbus, USA
Case–control study
156
Up to 39 patients had
lipase levels ≥ 3 ×
ULN w/o
pancreatitise
Variablee Variablee N/Ad N/Ad NR NR
Lott & Lu,
19918
Columbus, USA
Case–control study
100
Exact number with ↑
lipase NR
At least 6 patients had
lipase ≥ 3 × ULN w/o
pancreatitis
<200 U/l <140 U/l N/Ad N/Ad NR NR
Malloy et al.,
201228
San Diego, USA
Case–control study
1869
119 type 2 DM patients
and 29 obese
non-DM patients had
↑ lipase w/o
pancreatitis
13 type 2 DM patients
and 2 obese non-DM
patients had lipase
levels ≥ 3 × ULN w/o
pancreatitiss
0–60 U/l 13–53 IU/l
(pancreatic
amylase)
28 ± 20 (type 2
DM,
screening), 27
± 16 (type 2
DM, baseline);
26 ± 10
(obese,
screening), 26
± 10 (obese,
baseline)
42 ± 29 (type 2
DM,
screening), 43
± 33 (type 2
DM, baseline);
33 ± 26
(obese,
screening), 33
± 14 (obese,
baseline)
NR 0/119 patients
with ↑ lipase
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Author(s),
year
Hospital, country
Type of study
Patients in series and
patients with raised
lipase levels, n
Normal
range
of lipase
Normal
range of
amylase
Peak amylase level
(non-pancreatitis),
mean (range)
Peak lipase level
(non-pancreatitis),
mean (range)
Imaging
(CT ± others)
Presence of
abdominal pain/
tenderness
Manjuck
et al.,
200526
NY, USA
Prospective cohort
study
245
99 had ↑ lipase (11/99
had pancreatitis)
Number with lipase
levels ≥ 3 × ULN NR
23–208 U/l NR 140 (cf. 389 for
patients with
image-proven
pancreatitis)b
900 (cf. 2231 for
patients with
image-proven
pancreatitis)b
US features of
pancreatitis present
in 2 patients; CT
features of
pancreatitis present
in a further 9
patientsa
Difficult to
assessc
Masoero
et al.,
199650
Torino, Italy
Prospective cohort
study
212 (63 with CRF, 98
on HD, 28 on CAPD,
23 with renal
transplants)
118 had ↑ lipase levels
13 had lipase levels ≥ 3
× ULN (10 HD, 1
CAPD, 2 CRF)
23–300 U/l 0–200 U/l 390 ± 336 in HD
patients; 280 ±
128 in CRF
patients; 255 ±
109 in CAPD
patients; 209 ±
93 in RT
patients; 148 ±
64 in controls
389 ± 347 in HD
patients; 292 ±
211 in CRF
patients; 259 ±
177 in CAPD
patients; 175 ±
77 in RT
patients; 122 ±
62 in controls
US done in 40
patients with
particularly high
pancreatic enzyme
levels – no US
features of
pancreatitis in
these patients
0/212 patients
Matos et al.,
200962
Indianapolis and
Nashville, USA;
Mannheim and
Dresden, Germany
Retrospective case
series
17
4 had ↑ lipase levels
w/o pancreatitis
Number with lipase ≥ 3
× ULN NR
NR NR NR NR (maximum
4151)
NR 10/17 had
abdominal pain
(unclear if
same as those
patients with ↑
lipase)
Mitura &
Romanczuk,
200964
Siedlce, Poland
Case report
1
Had lipase level ≥ 3 ×
ULN
13–60 IU/l 28–100 IU/l 2113 3184 No US features of
pancreatitis (CT not
done)
Yes
(para-umbilical
pain)
Nair et al.,
200030
New York, USA
Prospective case
series
100
20 had ↑ lipase w/o
pancreatitis
17 had lipase levels ≥ 3
× ULN; of these, 9
did not have
pancreatitis
0–72 IU/l 0–330 IU/l NR NR CT done in the 17
patients with lipase
levels ≥ 3 × ULN –
8/17 had CT
features of
pancreatitis
27/100 patients
(number with ↑
lipase and
abdominal pain
NR)
Nsien et al.,
199231
Washington, USA
Retrospective case
series
3
All 3 had lipase levels ≥
3 × ULN
23–208 IU/l 20–150 IU/l 497 ∼3200 No CT features of
pancreatitis in any
patient
0/3 patientsl
Okumura
et al.,
199853
Otsu, Japan
Case report
1
Had lipase level ≥ 3 ×
ULN
5–160 IU/l 25–80 IU/l 73 1730 No CT or US features
of pancreatitis
Yes (NB lipase
measured
during Crohn's
disease
relapse)
Pezzilli et al.,
199769
Bologna, Italy
Prospective cohort
study
88
6 had ↑ lipase
1 had lipase levels ≥ 3
× ULN
24–270 IU/l 0–220 IU/l NR (range
22–728)
NR (range 5–826) No US features of
pancreatitis in all
6 patients with ↑
lipase
0/6 patients with
↑ lipase
Quiros et al.,
200832
Davis, Aurora and
Stanford, USA
Prospective cohort
study
67
21 had ↑ lipase w/o
pancreatitis; 14 of
these had abdo pain,
and 7 did not)
Number with lipase ≥ 3
× ULN NR
13–51 U/l 30–140 U/l 136 ± 295 94 ± 163 No imaging was done 42/67 patients
(upon
presentation);
14/21 patients
with ↑ lipase
Rosti et al.,
200972
Bergamo, Bologna,
Brescia, Catania,
Catanzaro, Naples,
Rome, Turin and
Udine, Italy
Prospective case
series
73
21 had ↑ lipase w/o
pancreatitis
3 had lipase levels > 5
× ULN w/o
pancreatitis
NR NR NR NR NR 0/21 patients
with ↑ lipase
Ryan et al.,
199427
Iowa, USA
Prospective cohort
study
100
17 had ↑ lipase (5 of
these had clinical
pancreatitis)
Number with lipase ≥ 3
× ULN NR
<190 U/l <170 U/l 544 ± 112 in
patients w/o
pancreatitis
(but raised
enzymes) cf.
725 ± 202 in
patients with
clinical
pancreatitis
716 ± 150 in
patients w/o
pancreatitis
(but raised
enzymes) cf.
882 ± 349 in
patients with
clinical
pancreatitis
No CT features of
pancreatitis in the
17 patients with ↑
lipase; US features
of pancreatitis in
1/17 patients with
↑ lipasey
5/17 patients
with ↑ lipasez
Semakula
et al.,
199670
Bonheiden, Brussels,
Ghent and Liege,
Belgium;
Stockholm,
Sweden
Prospective cohort
study
307
Numbers with ↑ lipase
NR)
0–9 years:
17–136 U/l;
10–19 years:
30–167 U/l;
20–39 years:
46–235 U/l
15–97 U/l 47 ± 21 (range
NR)
88 (range
12–4,177)
NR NR
Sinha et al.,
201065
London and
Southend-on-Sea,
UK
Case report
1
Had lipase level ≥ 3 ×
ULN
5–65 IU/l 25–125 IU/l 1121 1700 No CT features of
pancreatitis
Yes (epigastric,
then
generalized)
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Author(s),
year
Hospital, country
Type of study
Patients in series and
patients with raised
lipase levels, n
Normal
range
of lipase
Normal
range of
amylase
Peak amylase level
(non-pancreatitis),
mean (range)
Peak lipase level
(non-pancreatitis),
mean (range)
Imaging
(CT ± others)
Presence of
abdominal pain/
tenderness
Smith et al.,
200515
Sydney, Australia
Case–control study
1880
427 had ↑ lipase w/o
pancreatitisr
62 had lipase levels ≥ 3
× ULN w/o
pancreatitis
<190 U/l 27–100 U/l <100 (median) 190–285 (median) NR NR
Sutton et al.,
20095
Nottingham, UK
Case–control study
1520
Number with ↑ lipase
NR
41 had lipase levels ≥ 3
× ULN w/o
pancreatitis
<300 IU/l <110 IU/l NR NR NR NR
Taes et al.,
200054
Ghent, Belgium;
Columbus, USA
Case report
1
Had lipase level ≥ 3 ×
ULN
23–300 U/l 30–110 U/l ∼300 3764 No CT features of
pancreatitis (ERCP
showed minimal
dilation of
choledochus and
Wirsung duct)
Yes (patient
initially
admitted with
chronic
constipation
and
progressive
abdominal
distension with
lipase of 575)
Testoni et al.,
200922
Milan, Italy
Prospective cohort
study
25
11 had ↑ lipase
Number with levels ≥ 3
× ULN NR
0–60 IU/l 13–53 IU/l
(pancreatic
amylase)
NR (range
76–227)
NR (range
65–364)
0/25 had US, CT or
MRCP features of
pancreatitis; 2/25
had MRCP features
of chronic
pancreatitis; 8/25
had MRCP-S
features of chronic
pancreatitis
0/25 patients
Vantyghem
et al.,
199933
Lille, France
Prospective cohort
study
164 (52 had DKA, 90
had poorly-controlled
DM, 22 had
well-controlled DM,
27 were controls)
31 had ↑ lipase w/o
pancreatitis (19/52
patients with DKA
had ↑ lipasem);
Number with lipase
levels ≥ 3 × ULN NR
0–190 IU/l 0–160 IU/l 194 ± 270 (in
DKA group)
348 ± 690 (in
DKA group)
NRn NRo
Wen et al.,
200557
Taipei, Taiwan
Prospective case
series
37
12 had ↑ lipase w/o
pancreatitis
5 had levels ≥ 3 × ULN
w/o pancreatitis
<120 U/l <100 U/l NR (although no
child had levels
≥ 3 × ULN)
NR 0/37 had US features
of pancreatitis;
18/31 patients with
BA underwent MRI
and did not have
any features of
pancreatitis
0/37 patientsq
Yoffe et al.,
200337
Houston, USA
Case–control study
103
26 had ↑ lipase w/o
pancreatitis;
Number with lipase
levels ≥3 × ULN NR
114–286 U/l 25–115 U/l 82 ± 30 (cf. 75 ±
45 for controls)
253 ± 72 (cf. 210
± 42 for
controls)
NRp 0/103 patients
Yuki et al.,
199955
Izumo, Japan
Case report
1
Had lipase level ≥ 3 ×
ULN
0–50 IU/l 50–170 IU/l Peak NR (but >
ULN)
888 No US or CT features
of pancreatitis
Nil
Zachee
et al.,
198516
Antwerp, Belgium
Prospective case
series
40
26 had ↑ lipase levels
(3 of these patients
had pancreatitis)
Number with lipase
levels ≥ 3 × ULN NR
NR NR 4.6 ± 3.1 × ULN
(w/o
pancreatitis)
3.5 ± 3.9 × ULN
(w/o
pancreatitis)
NR 0/37 patients w/o
pancreatitis
Zaman et al.,
199456
Leuven, Belgium
Case report
1
Had lipase level ≥ 3 ×
ULN
23–208 U/l 30–85 U/l 1104 2600 NR NR
aImaging performed in a total of 50 patients with elevated lipase levels.
bMaximum mean amylase or lipase levels in the 39 of 50 patients with elevated lipase who underwent imaging but showed no radiologic features of pancreatitis.
cThe majority of patients with elevated lipase levels were intubated and sedated, and thus clinical features (e.g. abdominal tenderness) were hard to ascertain.
dMean for elevated lipase or amylase not provided as study explored non-uniform sets of patients with multiple different diagnostic categories (e.g. patients with abdominal pain compared with patients with
pancreatitis).
eExact number cannot be expressed as four different methods of lipase determination and two different methods of amylase measurement were utilized; not all four methods of lipase measurement were always
used in every patient; three to six of 14 patients with cholelithiasis and/or cholecystitis, four to 13 of 43 patients with inflammatory disorders of the biliary and gastrointestinal tract, two to five of 35 patients
with complications of renal transplantation, two to seven of 17 patients with renal failure, and two to eight of 22 patients with accidental trauma had lipase levels of ≥3 × ULN.
fIt is not specified whether any of the 10 patients with raised lipase underwent CT scanning; the three patients with biliary pathology had a normal pancreas.
gOne abdominal CT scan, and two US scans were performed over a 2-month period.
hExact value not recorded.
iTen patients had a ruptured AAA, six had a perforated duodenal ulcer and two had intestinal obstruction.
jDifferent patient subset from Gullo, 1996.18
kThe number of patients who were intubated/ventilated and/or had impaired sensorium (and thus would alter the reporting of abdominal pain or tenderness) was not reported in the article.
lOne of these patients was confused and one was drowsy on admission, which may have made abdominal pain difficult to assess.
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mNine of 52 DKA patients had chronic alcoholic pancreatitis with pancreatic calcifications, but not all patients with very high lipase levels in the DKA group had chronic pancreatitis.
nAlthough the number of patients who underwent CT scanning/other imaging was not recorded, the number of patients with ‘pancreatic calcifications’ is recorded in the text.
oAlthough the number of patients with abdominal pain was not recorded, the article text does state that ‘none of the [DKA] patients had clinical signs of acute pancreatitis’; this statement is not further
elaborated in the text.
pAlthough not recorded, those patients with lipase levels >2 × ULN were assessed by US.
qAbdominal pain may have been difficult to assess in some patients as the patients were all children, with an age range of 4 months to 11.2 years (median: 2.4 years).
rA diagnosis of severe pancreatitis was made in case of US or CT changes of acute pancreatitis; a diagnosis of indeterminate pancreatitis was made in case of abdominal pain consistent with pancreatitis but
no CT or US features of the disease.
sThis study looked at two separate groups that had been recruited for other large clinical trials: type 2 DM patients, and obese non-DM patients; lipase and pancreatic amylase levels were measured at the study
screening period, then at baseline prior to commencement of the other trials. Note that by the time of randomization (i.e. at baseline), only two (of 13) and non (of two) type 2 DM and obese non-DM patients,
respectively, still had lipase levels ≥ 3 × ULN.
tAlthough there were no specific recordings for amylase and lipase levels in patients without pancreatitis compared with patients with pancreatitis, some important results were as follows: mean peak amylase
and lipase levels in severe head injury were 460 ± 544 and 1027 ± 1643, respectively; in spontaneous ICH were 362 ± 253 and 854 ± 1143, respectively; in SAH and other vascular disease were 337 ± 256 and
552 ± 853, respectively; and in patients who had tumour bleeding during admission/operation were 341 ± 381 and 749 ± 972, respectively. With respect to the type of neurosurgical intervention, the highest
lipase levels were seen upon aneurysm clipping or other neurovascular surgery (551 ± 825) and upon insertion of external ventricular drains, intracranial pressure monitors and/or ventriculoperitoneal shunts
(547 ± 680).
uFour of 14 patients with elevated amylase and/or lipase had an abnormal pancreas on US, and seven of 11 had an abnormal pancreas on CT; in total, CT and/or US scanning were performed in 34 patients
(four patients underwent both US and CT scanning; in total nine patients were radiologically positive for pancreatitis). Indications for scanning were: symptoms/signs of pancreatitis, amylase >3 × ULN, lipase
>5 × ULN, positive peritoneal signs, and/or fever of unknown origin.
vAssessment made difficult by altered levels of consciousness in some/all patients.
wUnclear if this patient subset was also included in the other studies by this author (Gullo).20,21
xOf the 29 DKA patients with normal pancreatic enzymes, data on abdominal pain and/or vomiting were available for only 21.
yNo patient with persistently elevated amylase or lipase had CT features of pancreatitis; one patient had US features of pancreatitis; in total, five of 17 were clinically diagnosed as having pancreatitis.
zFive of 17 patients were clinically diagnosed as having pancreatitis (despite normal CT scans) according to failed enteral feeding + concomitant raised pancreatic enzymes + abdominal distension + epigastric
tenderness; one of these patients had a laparotomy.
aaSeven of 237 patients at some point had pancreatitis (preceding onset of IBD in two, concomitant with onset of IBD in two, and after onset of IBD in three); two of these had raised pancreatic enzyme(s).
bbCT scan was performed in patients with lipase >3 × ULN; although 38 patients had lipase higher than this threshold, 18 could not undergo imaging as a result of cardiopulmonary instability (n = 7), discharge
from ICU prior to CT (n = 7), death (n = 3) and subsequent withdrawal of consent (n = 1). Seven of 20 had morphological alterations of the pancreas on CT (in one patient only a small fluid collection was
detected at the pancreatic tail).
AAA, abdominal aortic aneurysm; CAPD, continuous ambulatory peritoneal dialysis; CD, Crohn’s disease; CR, case report; CRF, chronic renal failure; CT, computed tomography; DKA, diabetic ketoacidosis;
DM, diabetes mellitus; HD, haemodialysis; ICH, intracranial haemorrhage; MRCP, magnetic resonance cholangiopancreatography; MRCP-S, secretin-enhanced MRCP; MRI, magnetic resonance imaging;
NR, not recorded; SAH, subarachnoid haemorrhage; SOD, sphincter of Oddi dysfunction; UC, ulcerative colitis; ULN, upper limit of normal; US, ultrasonography; w/o, without.
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